Showing 1 - 4 results of 4 for search 'Marlon C Rebelatto', query time: 0.03s Refine Results
  1. 1
    Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy

    Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy by Andreas Spitzmüller, Thomas Herz, Marlon C. Rebelatto, Helene Kaplon, Brandon W. Higgs

    Published 2019-03-01
    Get full text
    Article
  2. 2
    Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay

    Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay by Paul Scorer, Marietta Scott, Nicola Lawson, Marianne J. Ratcliffe, Craig Barker, Marlon C. Rebelatto, Jill Walker

    Published 2018-07-01
    Get full text
    Article
  3. 3
    Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma

    Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma by Magdalena Zajac, Marietta Scott, Marianne Ratcliffe, Paul Scorer, Craig Barker, Hytham Al-Masri, Marlon C. Rebelatto, Jill Walker

    Published 2019-09-01
    Get full text
    Article
  4. 4
    Optimal PD-L1-high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy.

    Optimal PD-L1-high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy. by Magdalena Zajac, Jiabu Ye, Pralay Mukhopadhyay, Xiaoping Jin, Yong Ben, Joyce Antal, Ashok K Gupta, Marlon C Rebelatto, J Andrew Williams, Jill Walker

    Published 2020-01-01
    Get full text
    Article

Search Tools: